Search

Your search keyword '"Zsolt Balazs"' showing total 27 results
Start Over Author "Zsolt Balazs" Database OpenAIRE
27 results on '"Zsolt Balazs"'

1. Supplementary Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Tumor Profiler Consortium author list

Published
2023

2. Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST5: Table of the 15 most informative proteins upregulated in MEK inhibitor-resistant cell culture (ranked by log2 fold-change).

Published
2023

3. Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S13: Immunohistochemical analysis of CyTof biomarker panel.

Published
2023

4. Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S12: Analysis of CyTof data from fresh melanoma tissue

Published
2023

5. Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S15: Tumor response curves in mice for ionophoric copper-chelators in combination with binimetinib.

Published
2023

6. Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST7: Clinical data of the 62 melanoma patient which tumor material was used for pharmacoscopy

Published
2023

7. Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S16: scRNA-sequencing analysis of xenograft tumors M130227

Published
2023

8. Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST8: Data output of the CCLE cell line screening provided by Prof. Schreiber at Broad Institute.

Published
2023

9. Suppl. Figure S7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S7: Pathway enrichment (metabolomics)

Published
2023

10. Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S5: Elevated cytoplasmic ROS induces apoptosis after the treatment with neocuproine

Published
2023

11. Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S10: Clinical data of orthologic slice cultures

Published
2023

12. Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S9: Treatment of binimetinib-sensitive melanoma cell lines with PPP inhibitor

Published
2023

13. Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Metabolomics

Published
2023

14. Suppl. Figure S1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S1: Evaluation of HST screening.

Published
2023

15. Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST6: Differential expressed lipids and their FDRs in sensitive vs resistant cells (negative values are upregulated in sensitive cells).

Published
2023

16. Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S4: Neocuproine is a copper-dependent ROS inducer

Published
2023

17. Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST1: Summary of growth inhibitory IC50 values (including the corresponding 95% confident intervals (C.I.95%) conducted for neocuproine or MEKi (binimetinib) and primary human cell lines. The table includes the confirmed oncogenic mutation as well as the ratio of neocuproine normalized to the MEKi response.

Published
2023

18. Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST4: Table of the 15 most informative proteins upregulated in MEK inhibitor-sensitive cell culture (ranked by log2 fold-change).

Published
2023

19. Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S3: Correlation between MEKi responsiveness and sensitivity to nNeocuproine

Published
2023

20. Data from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Clinical management of melanomas with NRAS mutations is challenging. Targeting MAPK signaling is only beneficial to a small subset of patients due to resistance that arises through genetic, transcriptional, and metabolic adaptation. Identification of targetable vulnerabilities in NRAS-mutated melanoma could help improve patient treatment. Here, we used multiomics analyses to reveal that NRAS-mutated melanoma cells adopt a mesenchymal phenotype with a quiescent metabolic program to resist cellular stress induced by MEK inhibition. The metabolic alterations elevated baseline reactive oxygen species (ROS) levels, leading these cells to become highly sensitive to ROS induction. In vivo xenograft experiments and single-cell RNA sequencing demonstrated that intratumor heterogeneity necessitates the combination of a ROS inducer and a MEK inhibitor to inhibit both tumor growth and metastasis. Ex vivo pharmacoscopy of 62 human metastatic melanomas confirmed that MEK inhibitor–resistant tumors significantly benefited from the combination therapy. Finally, oxidative stress response and translational suppression corresponded with ROS-inducer sensitivity in 486 cancer cell lines, independent of cancer type. These findings link transcriptional plasticity to a metabolic phenotype that can be inhibited by ROS inducers in melanoma and other cancers.Significance:Metabolic reprogramming in drug-resistant NRAS-mutated melanoma cells confers sensitivity to ROS induction, which suppresses tumor growth and metastasis in combination with MAPK pathway inhibitors.

Published
2023

21. Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S6: Correlation analysis between MEKi and ROS.

Published
2023

22. Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST2: Summary of the clinical data corresponding to the primary cell cultures used in this publication

Published
2023

23. Suppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S8: Lipidomics

Published
2023

24. Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

Table ST3: Differential expressed RNA transcripts between MEKi-sensitive and -resistant melanoma cell cultures.

Published
2023

25. Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S2: HPLC analysis of STO13881 and nNeocuproine showed overlapping profiles and confirmed STO13881 to be neocuproine (purchased from Sigma-Aldrich, Switzerland). High-performance liquid chromatography (HPLC) analysis was performed using the Zuürich functional genomic center.

Published
2023

26. Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Author

Mitchell P. Levesque, Reinhard Dummer, Berend Snijder, Martin Distel, Thorsten Hornemann, Stuart L. Schreiber, Michael Krauthammer, Andreas Dzung, Annalisa Saltari, Andrea Aloia, Judith Wenzina, Vasanthi S. Viswanathan, Alaa Othman, Julien Mena, Rebekka Wegmann, Pål Johansen, Susana Pascoal, Aizhan Tastanova, Zsolt Balazs, Anja Irmisch, Nicola Zamboni, Andrea Bileck, Alexander Leitner, Phil F. Cheng, Verena Paulitschke, Nina Zila, Gergely Karsai, Patrick Turko, Luzia Briker, Jan Käsler, Corinne I. Stoffel, and Ossia M. Eichhoff

Abstract

S14: CCLE cancer cell panel analysis for the responses to neocuproine

Published
2023

27. Memory Th1 cells modulate heterologous diseases through innate function

Author

Nikolas Rakebrandt, Nima Yassini, Anna Kolz, Michelle Schorer, Katharina Lambert, Celine Rauld, Zsolt Balazs, Michael Krauthammer, José M. Carballido, Anneli Peters, and Nicole Joller

Abstract

Through immune memory, infections have a lasting effect on the host. While memory cells enable accelerated and enhanced responses upon re-challenge with the same pathogen, their impact on susceptibility to unrelated diseases is unclear. We identify a subset of memory T helper 1 (Th1) cells termed innate acting memory T (TIA) cells that originate from a viral infection and produce IFN-γ with innate kinetics upon heterologous challengein vivo. Activation of memory TIAcells is induced in response to IL-12 in combination with IL-18 or IL-33 but is TCR-independent. Rapid IFN-γ production by memory TIAcells is protective in subsequent heterologous challenge with the bacterial pathogenLegionella pneumophila. In contrast, antigen-independent re-activation of CD4+memory TIAcells accelerates disease onset in an autoimmune model of multiple sclerosis. Our findings demonstrate that memory Th1 cells can acquire additional TCR-independent functionality to mount rapid, innate-like responses that modulate susceptibility to heterologous challenges.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results